Navigation Links
BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Date:5/8/2008

alleviation of symptoms are consistent with prior

Phase II study results of the 300mg dose of i.m. peramivir.

-- Reductions in viral shedding and percentage of patients shedding virus

were consistent with the data seen in our previous phase II study.

-- Pharmacokinetic data in the treated population indicate that patients

achieved consistent drug levels, which were similar to those seen in

our previous well-controlled Phase I trial.

BioCryst is continuing development of a more concentrated formulation and plans to test higher doses of i.m. peramivir in the next Phase II study. The doses to be studied in Phase II will be selected based on a planned mid 2008 analysis of the ongoing Phase I study of the more concentrated formulation.

"We are encouraged by the signs of activity of i.m. peramivir and are prepared to move forward and evaluate a higher dose. The consistency seen between the results of our recent clinical trials gives us confidence that i.m. peramivir has the potential to be an effective treatment for influenza," stated Dr. Thomas J. Simon, Interim Chief Medical Officer.

BCX-4208 development update

Following review of a planned interim analysis of the ongoing Phase IIa trial of BCX-4208 in psoriasis, Roche has terminated its license agreement for the development of BCX-4208 for autoimmune diseases and transplant. As a result, BioCryst will regain worldwide rights to BCX-4208. Roche and BioCryst have agreed to complete the ongoing Phase IIa trial. The planned interim analysis showed that BCX-4208 was safe and well-tolerated; clinical efficacy was not demonstrated.

The ongoing Phase IIa trial is a randomized, double blind, placebo controlled, dose ranging study in 66 patients with moderate to severe plaque psoriasis. BCX-4208 is administered once a day for 6 weeks at a dose of either 20mg or 120mg. The primary objectives of this study are to assess the safety, tolerability, an
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... the health of your heart, researchers have discovered. , ... standard TENS machine like those designed to relieve labour ... small raised flap at the front of the ear ... stimulation changed the influence of the nervous system on ... drive failing hearts too hard. , Professor Jim Deuchars, ...
(Date:8/19/2014)... One of the major limitations in ... vascular supply. Nutrient and gas transport throughout synthetic ... for successful regeneration and integration into the patient’s ... vascularization and promote angiogenesis in a variety of ... and architecture, and enhancing scaffolds with stem cells. ...
(Date:8/19/2014)... Pa. , Aug. 19, 2014 A ... has been nominated for a Centers for Disease Control ... addressing a major public health concern. ... System, is one of a team of researchers nominated ... Charles C. Shepard Science Award for Data Methods and ...
(Date:8/19/2014)... Jolla, CA (PRWEB) August 19, 2014 ... toll Parkinson’s disease can take on an individual. ... extremities, decreased facial expression, problems swallowing and severe depression. ... to the dying off of dopamine producing neurons of ... themselves from a disease that slowly and progressively gets ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... Corporation (OTCBB:RONE), an emerging business development corporation that is ... companies, today announced it will distribute a special dividend ... stock. Regal One is assisting in the filing of ... and Exchange Commission, wherein these shares may be registered ...
... Alliance released the results of its Oncology National Commercial (ONC) ... report of the study,s findings is available at www.campbellalliance.com ... of the results with its clients by request. ... changes in the oncology market over the past 10 years ...
... 31, 2011 Enox Biopharma, Inc., a leader in ... medical devices, today announced that it has expanded its ... a patent application on novel means of delivering nitric ... well recognized as both an antimicrobial agent which can ...
Cached Biology Technology:Regal One Announces Dividend of Rampart Detection Systems Common Stock 2Oncology National Commercial (ONC) Study Outlines 10 Trends Shaping the Market for Oncology Pharmaceutical and Biotech Products 2Enox Biopharma, Inc. Expands Its Technology to Cover the Wound Care Market 2
(Date:8/19/2014)... systems be used in supermarkets to encourage healthier spending ... to answer that very question by tracking the purchasing ... Stars System to rate the nutritional value of foods ... Brand Lab,s David Just, PhD, and Brian Wansink PhD, ... records of over 150 Hannaford Supermarkets in the Northeastern ...
(Date:8/19/2014)... fish purchased at retail seafood counters in 10 ... can expose consumers to unexpectedly high levels of ... falsely present a fish of the same species, ... dangerous mislabeling offense, according to new research by ... labeling of seafood is essential to allow consumers ...
(Date:8/19/2014)... crocodiles colonised the seas during warm phases and became ... study which establishes a link between marine crocodilian diversity ... of more than 140 million years. , The ... de Lyon, France and formerly from the University of ... Communications ., Today, crocodiles are ,cold-blooded, animals that mainly ...
Breaking Biology News(10 mins):Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Evolution of marine crocodilians constrained by ocean temperatures 2
... of Colorado-Denver and Health Sciences Center and Stanford University ... respond to DNA damage and other acute stresses, and ... lead to new diagnostic markers and cancer treatments with ... the May 21 advanced online version of the journal ...
... forms could be the answer to one of today's ... future. Using a variety of natural food sources, ... fuels like ethanol and even boost the output of ... week at the 106th General Meeting of the (ASM) ...
... Tregs are a specialized subpopulation of T cells that ... harnessing the therapeutic potential of Tregs -- for example, ... arthritis -- is hampered by problems generating sufficient cells ... T cells, Tregs do not proliferate in vitro when ...
Cached Biology News:Researchers uncover new mechanism of tumor suppressor 2Research highlights how bacteria produce energy 2